ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, ALX-0061, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
(Thomson Reuters ONE) -
GHENT, Belgium, 12 June 2013 - Ablynx [Euronext Brussels: ABLX] today announced
that it will have an oral and poster presentation on its novel anti-IL-6R
Nanobody, ALX-0061, at the Annual European Congress of Rheumatology (EULAR),
which takes place from 12 to 15 June 2013 in Madrid, Spain.
The oral presentation will demonstrate the strong efficacy and safety profile of
ALX-0061 at the 24 week final analysis of the Phase II part of a combined Phase
I/II study in patients with moderately to severely active rheumatoid arthritis
on a stable background of methotrexate. The pooled data at week 24 show that
treatment with ALX-0061 results in an ACR20 improvement of 84% and a 58% DAS28
remission. At all doses tested, ALX-0061 was well tolerated and clinically
relevant neutropenia was absent as well as serious infections. Clinically
significant signals in lipids were not observed and no anti-drug antibodies were
detected.
The abstract "Twenty-four weeks of treatment with a novel anti-IL-6 receptor
Nanobody resulted in 84% ACR20 improvement and 58% DAS28 remission in a Phase
I/II study in RA" is available on the EULAR website at http://www.eular.org.
(Abstract No. OP0043; Oral Presentation on Thursday, 13 June at 10.50h CET in
Hall 4).
The poster presentation will include data from in vitro experiments that
assessed the biological activity and affinity for both the soluble and membrane-
bound IL-6-receptor of ALX-0061 as compared to tocilizumab (Actemra®). The in
vitro results demonstrate the preferential inhibition of soluble Il-6R trans-
signalling by ALX-0061 could provide superior therapeutic efficacy with a better
side effect profile than tocilizumab.
The abstract "ALX-0061, an anti-IL-6R Nanobody for use in rheumatoid arthritis,
demonstrates a different in vitro profile as compared to tocilizumab" is
available on the EULAR website at http://www.eular.org. (Abstract No. FRI0021;
Poster Presentation on Friday, 14 June at 11.45h CET in the Poster Area).
About ALX-0061
ALX-0061 targets the interleukin 6 pathway via its IL-6receptor (IL-6R), which
plays a fundamental role in the inflammation process in RA. ALX-0061 has been
designed to become a best-in-class therapeutic. Its small size (26kD) should
allow ALX-0061 to penetrate more effectively into tissues. The potent,
monovalent interaction of the molecule with its target reduces the possibility
of off-target effects. Its binding to human serum albumin prolongs the in vivo
half-life of the product and can lead to improved trafficking to areas of
inflammation. The Nanobody has a very strong affinity for soluble IL-6R, which
should ensure fast target engagement and could result in a fast onset of effect.
ALX-0061 appears to benefit from the general Nanobody characteristic of having a
very low immunogenic potential. ALX-0061 is a very robust and stable drug
product that is already manufactured at a multi-thousand litre scale. It can be
administered both intravenously and subcutaneously.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent,
Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx(at)mcomgroup.com
press release in pdf:
http://hugin.info/137912/R/1708715/566172.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1708715]
Unternehmensinformation / Kurzprofil:
Datum: 12.06.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 268799
Anzahl Zeichen: 5454
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX TO PRESENT DATA ON ITS ANTI-IL-6R NANOBODY, ALX-0061, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
